POST Online Media Lite Edition



 

EU lawmaker warns of risks from UK hasty approval of Pfizer coronavirus vaccine

Christian Fernsby |
Britain's emergency approval of the experimental coronavirus vaccine being developed by Pfizer and BioNTech is problematic as it was done too hastily, a prominent European Union lawmaker said.

Article continues below



Topics: PFIZER   

"I consider this decision to be problematic and recommend that EU Member States do not repeat the process in the same way.

A few weeks of thorough examination by the European Medicines Agency (EMA) is better than a hasty emergency marketing authorisation of a vaccine," said Peter Liese, an EU lawmaker who is a member of German Chancellor Angela Merkel's party.


What to read next

Trump announces new vaccine contract
Trudeau pledges over 300 mln USD for coronavirus vaccine access program
Germany to start coronavirus vaccinations by mid-December